Michael A. Zientek

发表

Reaction Phenotyping: Advances in the Experimental Strategies Used to Characterize the Contribution of Drug-Metabolizing Enzymes

Kuresh Youdim, K. Youdim, Michael A. Zientek, 2015, Drug Metabolism and Disposition.

Molybdenum‐Containing Hydroxylases

M. Hutzler, M. Zientek, Michael A. Zientek, 2012 .

Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR.

Paolo Vicini, Deepak Dalvie, Chengyi Zhang, 2017, Journal of medicinal chemistry.

Contribution of Extrahepatic Aldehyde Oxidase Activity to Human Clearance

Jangir Selimkhanov, S. Heyward, Michael A. Zientek, 2021, Drug Metabolism and Disposition.

In Vitro-In Vivo Correlation for Intrinsic Clearance for Drugs Metabolized by Human Aldehyde Oxidase

Kuresh Youdim, Michael Zientek, R. Obach, 2010, Drug Metabolism and Disposition.

Effect of intestinal glucuronidation in limiting hepatic exposure and bioactivation of raloxifene in humans and rats.

R. Obach, D. Dalvie, Michael A. Zientek, 2008, Chemical research in toxicology.

Cancer Therapy : Preclinical Targeting Small Cell Lung Cancer Harboring PIK 3 CA Mutation with a Selective Oral PI 3 K Inhibitor PF-4989216

K. Liu, T. Smeal, M. Yin, 2014 .

Targeting Small Cell Lung Cancer Harboring PIK3CA Mutation with a Selective Oral PI3K Inhibitor PF-4989216

K. Liu, T. Smeal, M. Yin, 2013, Clinical Cancer Research.

Identification of Novel Substrates for Human Cytochrome P450 2J2

Caroline A. Lee, J. Jones, D. Dalvie, 2010, Drug Metabolism and Disposition.

Relative Contributions of Cytochrome CYP3A4 Versus CYP3A5 for CYP3A-Cleared Drugs Assessed In Vitro Using a CYP3A4-Selective Inactivator (CYP3cide)

R. Obach, R. Walsky, T. Goosen, 2014, Drug Metabolism and Disposition.

DMD057000 1163..1173

R. Walsky, T. Goosen, Jennifer J. Harris, 2014 .

Relative Contributions of Cytochrome CYP 3 A 4 Versus CYP 3 A 5 for CYP 3 A-Cleared Drugs Assessed In Vitro Using a CYP 3 A 4-Selective Inactivator ( CYP 3 cide ) s

R. Obach, R. Walsky, T. Goosen, 2014 .

Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants.

Deepak Dalvie, Michael Zientek, Rose Ann Ferre, 2016, Journal of medicinal chemistry.

Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design.

D. Knighton, K. Liu, M. Yin, 2010, ACS medicinal chemistry letters.

Selective Mechanism-Based Inactivation of CYP3A4 by CYP3cide (PF-04981517) and Its Utility as an In Vitro Tool for Delineating the Relative Roles of CYP3A4 versus CYP3A5 in the Metabolism of Drugs

G. S. Walker, R. Obach, R. Walsky, 2012, Drug Metabolism and Disposition.

Dihydroxyphenylisoindoline amides as orally bioavailable inhibitors of the heat shock protein 90 (hsp90) molecular chaperone.

K. Gajiwala, M. Hickey, P. Kung, 2010, Journal of medicinal chemistry.

Microsoft Word-90329935-file00.docx

K. Youdim, M. Zientek, Michael A. Zientek, 2014 .

In Vitro Kinetic Characterization of Axitinib Metabolism

G. S. Walker, J. Bauman, T. Goosen, 2016, Drug Metabolism and Disposition.

DMD065615 102..114

G. S. Walker, J. Bauman, T. Goosen, 2015 .

2 Running Title : In vitro metabolism of axitinib

G. S. Walker, J. Bauman, T. Goosen, 2015 .

Toward a Consensus on Applying Quantitative Liquid Chromatography‐Tandem Mass Spectrometry Proteomics in Translational Pharmacology Research: A White Paper

Jill Barber, Bhagwat Prasad, Amin Rostami-Hodjegan, 2019, Clinical pharmacology and therapeutics.

Strategies for a comprehensive understanding of metabolism by aldehyde oxidase

Deepak Dalvie, R. Obach, D. Dalvie, 2013, Expert opinion on drug metabolism & toxicology.

Analytical approaches to determine cytochrome P450 inhibitory potential of new chemical entities in drug discovery.

L. Cohen, N. Sadagopan, Michael A. Zientek, 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Simultaneous determination of multiple CYP inhibition constants using a cocktail-probe approach.

K. Youdim, Michael A. Zientek, 2013, Methods in molecular biology.

Drug–Drug Interactions: Screening for Liability and Assessment of Risk

R. Obach, K. Youdim, M. Wester, 2009 .

Development of an in vitro drug-drug interaction assay to simultaneously monitor five cytochrome P450 isoforms and performance assessment using drug library compounds.

Caroline A. Lee, Douglas Burdette, R. Hyland, 2008, Journal of pharmacological and toxicological methods.

Differentiation of Cytochrome P450-Mediated from Non-CYP-Mediated Metabolism: Aldehyde Oxidase and Xanthine Oxidoreductase

M. Zientek, Michael A. Zientek, K. Kozminski, 2021, Methods in Pharmacology and Toxicology.

Why Do Most Human Liver Cytosol Preparations Lack Xanthine Oxidase Activity?

Jeffrey P. Jones, Erin G. Schuetz, Timothy Wong, 2014, Drug Metabolism and Disposition.

Microsoft Word-42679771-file00.docx

E. Schuetz, K. Thummel, J. T. Barr, 2014 .

DMD056374 695..699

Jeffrey P. Jones, S. Strom, E. Schuetz, 2014 .

Metabolism of Xenobiotics by Aldehyde Oxidase

D. Dalvie, Michael A. Zientek, 2015, Current protocols in toxicology.

Mechanism-Based Inactivation of Cytochrome P450 2C9 by Tienilic Acid and (±)-Suprofen: A Comparison of Kinetics and Probe Substrate Selection

Michael Zientek, Timothy S Tracy, T. Tracy, 2009, Drug Metabolism and Disposition.

Quantifying and Predicting the Promiscuity and Isoform Specificity of Small-Molecule Cytochrome P450 Inhibitors

W. Atkins, A. Nath, M. Zientek, 2010, Drug Metabolism and Disposition.

Microsoft Word-43909582-file00

W. Atkins, A. Nath, B. Burke, 2010 .

Integrated in silico-in vitro strategy for addressing cytochrome P450 3A4 time-dependent inhibition.

Sean Ekins, Ying Jiang, Michael West, 2010, Chemical research in toxicology.

Microsoft Word-39303196-file00

D. Dalvie, M. Wester, R. Totah, 2009 .

Clearance Prediction of Targeted Covalent Inhibitors by In Vitro-In Vivo Extrapolation of Hepatic and Extrahepatic Clearance Mechanisms

M. Dowty, A. Thorarensen, C. Banfield, 2017, Drug Metabolism and Disposition.

Characterization of cytochrome P450-mediated bioactivation of a compound containing the chemical scaffold, 4,5-dihydropyrazole-1-carboxylic acid-(4-chlorophenyl amide), to a chemically reactive p-chlorophenyl isocyanate intermediate in human liver microsomes.

A. Mutlib, C. Bigge, M. Jalaie, 2009, Chemical research in toxicology.

Industry Perspective on the Pharmacokinetic and Absorption, Distribution, Metabolism, and Excretion Characterization of Heterobifunctional Protein Degraders

Sara C. Humphreys, Donglu Zhang, C. Rynn, 2023, Drug Metabolism and Disposition.

Direct Comparison of the Prediction of the Unbound Brain-to-Plasma Partitioning Utilizing Machine Learning Approach and Mechanistic Neuropharmacokinetic Model

Y. Kosugi, Michael A. Zientek, Natalie Hosea, 2021, The AAPS Journal.

K. Gajiwala, N. Sach, Sherry L. Niessen, 2016, Journal of medicinal chemistry.

Identification of Novel Substrates for Human Cytochrome P450 2J2

Caroline A. Lee, D. Dalvie, M. Wester, 2010, Drug Metabolism and Disposition.

Why Do Most Human Liver Cytosol Preparations Lack Xanthine Oxidase Activity?

Jeffrey P. Jones, S. Strom, E. Schuetz, 2014, Drug Metabolism and Disposition.

Characterization of endothelin converting enzyme from intact cells of a permanent human endothelial cell line EA.hy926

K. Ahn, Michael A. Zientek, P. M. Guy, 1996, Biochemistry and molecular biology international.